Zynerba Press Releases

15 Nov 21 Zynerba Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Highlights

21 Oct 21 Zynerba Pharmaceuticals Announces Presentations at Two Upcoming Scientific Conferences in October

19 Oct 21 Zynerba Pharmaceuticals Announces Presentation of Poster at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit

8 Oct 21 Zynerba Pharmaceuticals Announces Presentation of Poster at the 2021 American Academy of Pediatrics National Conference & Exhibition

20 Sep 21 Zynerba Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference

13 Sep 21 Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome

9 Sep 21 Zynerba Pharmaceuticals Presents Longer Term Tolerability and Efficacy Data of Zygel™ in Children and Adolescents with Autism Spectrum Disorder (ASD) at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021

7 Sep 21 Zynerba Pharmaceuticals Announces Publication of Results of Phase 2 BELIEVE Open-Label Study of Zygel™ in Children and Adolescents with Developmental and Epileptic Encephalopathies (DEE) in JAMA Network Open

2 Sep 21 Zynerba Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

2 Sep 21 Zynerba Pharmaceuticals Announces Oral Presentations at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021